Pangaea Ventures’ Post

Metagenomic Analysis Reveals Bacteria Linked to Gallbladder Cancer! 🦠 Excited to share that Team Bionivid Technology Private Limited has contributed to metagenomics analysis in collaboration with Prof. Vinay Kapoor from Mahatma Gandhi Hospital and Dr. Yasuo Tsuchiya from Niigata University, Japan. Together, we have identified a significant link between specific biliary bacteria and gallbladder cancer (GBC). Using 16S rRNA-based metagenomic analysis, scientists analysed the biliary microbiota in patients with GBC and gallstones-associated chronic cholecystitis.  We look forward to more exciting collaborative efforts ahead! Team Bionivid - Rohit Shukla, Vinita Menon and Roli Budhwar Ph.D. Read more about this research 🔗- https://lnkd.in/gshF7dUx #TheGenomeEducation #GenomeStation #Genomics #GenomicsCompany #GenomeSequencing #GenomicResearch #GenomeScience #Biotech #Biotechnology #Bioinformatics #GenomeStation #NGSAnalyticsPlatform #AutomatedAnalytics #NGS #NextGenerationSequencing #WGS #WholeGenomeSeq #Microbiome #GallbladderCancer #Metagenomics #HealthResearch #TeamBionivid

Metagenomic Analysis Reveals Bacteria Linked to Gallbladder Cancer! 🦠 Excited to share that Team Bionivid Technology Private Limited has contributed to metagenomics analysis in collaboration with Prof. Vinay Kapoor from Mahatma Gandhi Hospital and Dr. Yasuo Tsuchiya from Niigata University | 新潟大学 University, Japan. Together, we have identified a significant link between specific biliary bacteria and gallbladder cancer (GBC). Using 16S rRNA-based metagenomic analysis, scientists analysed the biliary microbiota in patients with GBC and gallstones-associated chronic cholecystitis.  We look forward to more exciting collaborative efforts ahead! Team Bionivid - Rohit Shukla, Vinita Menon and Roli Budhwar Ph.D. Read more about this research 🔗- https://lnkd.in/gshF7dUx #TheGenomeEducation #GenomeStation #Genomics #GenomicsCompany #GenomeSequencing #GenomicResearch #GenomeScience #Biotech #Biotechnology #Bioinformatics #GenomeStation #NGSAnalyticsPlatform #AutomatedAnalytics #NGS #NextGenerationSequencing #WGS #WholeGenomeSeq #Microbiome #GallbladderCancer #Metagenomics #HealthResearch #TeamBionivid

This sounds absolutely incredible: treating and preventing colorectal cancer with bacteria the bacteria that some of us already have in our intestines The live biotherapeutic product is in the pre-clinical stage. “We are now starting to work with the drug substance," Ana Montalban-Arques, the CEO of Recolony says on the new X-Health.show episode. "So with these freeze-dried bacteria that we will eventually encapsulate in gastric-resistant capsules, to give it orally to the patients. We are already working on that and we are testing the safety and efficacy in our animal models. With this one, we expect to reach the clinic by the end of next year. And the second project which is in the discovery phase is the small molecule project that is based on the discovery of the mechanism of action.” You’ll also hear about 👉 what is a dysbiotic gut microbiome 👉 the gut microbiome and its influence on colorectal cancer 👉 studies of specific strains of bacteria that show reducing cancer in mice Recolony AG is a Swiss startup, a spin-off from the University of Zurich. They aim to develop a bacteria-based oral therapy to treat and prevent colorectal cancer. No chemotherapy, no side effects – oral administration at home. Listen to the whole story – link in the comments. #cancertreatment #biotech #biotechnology #futureofhealthcare #swissstartups #xhealth Wyss Zurich Buzzsprout

📢 PODCAST ALERT 📢 Project Leader Ana Montalban-Arques from our current project Recolony (Recolony AG) was recently featured in X-Health.show #podcast series with host, Aleksandra Jani, MCIM. Recolony is developing a bacteria-based oral #therapy for colorectal #cancer that consists primarily of selected #bacteria of the gut microbiota. With this approach, Ana and her team aims to develop a new class of drugs for the #treatment and #prevention of cancer. Listen to Ana's story below 👇 #wysszurich #cancertherapy #cancerresearch #oralcancertreatment #fightcancer #futureofcancertherapy #biotechresearch #biotechinnovation #startup

NGS Revolutionizing Cancer Research: Advantages & Applications #NGS #cancerresearch #biotechnology #genomics #omics #genomics #cancer #cancerbiology #biology #drjyotibala #molelixirinformatics

🔔Our latest report in the "Uncovering White Spaces for biotics" series is now available for purchase! Our 'Uncovering White Spaces: Cancer and the Microbiome' report enables you to explore some of the potential implications of the emerging area of #microbiomescience in the context of #oncology, and what this could mean for the makers of pre, pro, and postbiotic products. 🔎 What this report tells you: 1.   Which lines of microbiome research are currently being pursued by prominent cancer NGOs and biotech/pharma companies 2.   The potential of microbiota precision medicine to reshape current approach to cancer prevention, early diagnosis, treatment and recovery 3.   The potential of #biotics in the patient-centric chemo and radio therapy 4.   Scan of relevant scientific studies published in the last three years carried out on pro/pre/postbiotics 5.   What types of biotic supplements are currently on the market espousing cancer-related claims, what kinds of claims these are This report is intended for educational purpose only, the objective is to show the state of the art in the cancer and the microbiome research and market development domain. If you're not a customer yet and would like to learn more about what we offer, you can reach out to the Lumina team at eddie.pticek@wrbm.com to find out more.   Buy the report 👉 https://bit.ly/3UbroOs

💡 Reporting on: #Cancer and the #Microbiome - the state of the art in the cancer and the microbiome research and market development domain. Not to be missed! #NGOs #Biotech #science #probiotics #prebiotics #postbiotics #metabolites

In the world of science, sometimes things just don’t go as planned. The paper "Microbiome analyses of blood and tissues suggest cancer diagnostic approach" by Poore et al. has officially been retracted. 🚫🧬 Turns out, finding robust microbial signatures for cancer diagnosis is trickier than spotting Bigfoot in the wild. 🦶🔬 Kudos to the editors for maintaining scientific integrity. Let’s all take a moment to appreciate the highs and lows of the research journey – and remember, even retractions can be a step forward! This is a great reminder to be careful before hitting that 'publish' button. It’s better to get it right than to publish or perish. Here's to the never-ending quest for knowledge, and to learning from our missteps. 🥂 #ResearchLife #RetractionReaction #KeepCalmAndCarryOn #BetterThanPublishOrPerish

🔬 We are excited to announce the addition of a new omics data type on OmicsChart platform! We now support an interactive 𝐬𝐢𝐧𝐠𝐥𝐞-𝐜𝐞𝐥𝐥 𝐑𝐍𝐀 𝐬𝐞𝐪𝐮𝐞𝐧𝐜𝐢𝐧𝐠 (scRNA-seq) data browser from real-world cancer patients. This technology provides insights into molecular complexities inside the tumour, allowing identification of rare cell populations and key pathways for potential therapeutic targets. Curious about how integrating scRNA-seq with multi-omics approaches can accelerate your target discovery efforts? Contact us for an OmicsChart demo at ✉️𝐬𝐚𝐥𝐞𝐬@𝐨𝐦𝐢𝐜𝐬𝐜𝐡𝐚𝐫𝐭.𝐜𝐨𝐦🚀 #scRNAseq #multiomics #transcriptomics #genomics #omics #proteomics #metabolomics #RNAseq #oncology #CancerResearch #PrecisionOncology #oncologyresearch #cancerbiology #translationalbiology #translationaloncology #immunooncology #BiomarkerDiscovery #DrugDiscovery #PrecisionMedicine #targetdiscovery #rwd #realworlddata #rwe #clinicaltrials #bioinformatics #computationalbiology #biotech #startup #techbio #healthtech  

Quotient Therapeutics, underpinned by Sanger technology, and built by Flagship Pioneering, is presented today. The company focuses on the study of genetic variation at the cellular level to discover therapeutics informed by new links between #genes and #disease. Its academic Co-Founders include Dr Iñigo Martincorena, Prof Sir Mike Stratton and Dr Peter Campbell. Leveraging the Sanger Institute’s research on how tissues accumulate mutations, age and acquire diseases such as cancer, the company aims to develop transformative therapies intended to cure, prevent, or reverse disease. 💊 🧬 #Genomics #Innovation #therapeutics Read the announcement ⬇ https://bit.ly/40MeFD4